We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
176
BridgeBio Pharma
BBIO
$15.7B
– –
-188,767
Closed -$11.5M
BPMC
177
DELISTED
Blueprint Medicines
BPMC
– –
-122,699
Closed -$10.8M
CLDX icon
178
Celldex Therapeutics
CLDX
$2.96B
– –
-7,053
Closed -$236K
CNC icon
179
Centene
CNC
$31.5B
– –
-67,290
Closed -$4.91M
COGT icon
180
Cogent Biosciences
COGT
$6.64B
– –
-537,742
Closed -$4.36M
EDIT icon
181
Editas Medicine
EDIT
$407M
– –
-15,190
Closed -$860K
EXEL icon
182
Exelixis
EXEL
$13.8B
– –
-499,657
Closed -$9.1M
GRFS
183
Grifois
GRFS
$5.35B
– –
-47,373
Closed -$822K
INCY icon
184
Incyte
INCY
$24B
– –
-107,687
Closed -$9.06M
INSM icon
185
Insmed
INSM
$21.3B
– –
-98,387
Closed -$2.8M
IOVA icon
186
Iovance Biotherapeutics
IOVA
$1.93B
– –
-468,538
Closed -$12.2M
MDGL icon
187
Madrigal Pharmaceuticals
MDGL
$11.1B
– –
-13,340
Closed -$1.3M
NKTR icon
188
Nektar Therapeutics
NKTR
$2.38B
– –
-12,029
Closed -$3.1M
OVID icon
189
Ovid Therapeutics
OVID
$435M
– –
-372,733
Closed -$1.46M
PSNL icon
190
Personalis
PSNL
$1.41B
– –
-179,731
Closed -$4.55M
REPL icon
191
Replimune Group
REPL
$1B
– –
-219,060
Closed -$8.42M
RGNX icon
192
Regenxbio
RGNX
$638M
– –
-21,700
Closed -$843K
SAGE
193
DELISTED
Sage Therapeutics
SAGE
– –
-114,119
Closed -$6.48M
TFX icon
194
Teleflex
TFX
$6.18B
– –
-2,200
Closed -$884K
YMAB
195
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-197,820
Closed -$6.69M
DCPH
196
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-307,703
Closed -$11.3M
CBAY
197
DELISTED
Cymabay Therapeutics
CBAY
– –
-88,102
Closed -$384K
RETA
198
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-38,219
Closed -$5.41M
MTEM
199
DELISTED
Molecular Templates, Inc.
MTEM
– –
-13,295
Closed -$1.56M
JNCE
200
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-382,237
Closed -$2.6M
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.